ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- NewTheScientificWorldJournal · 2025Pooled it
- One Health Insights From Pteropus medius: Nipah Virus Spillover, Microbiota, and Antimicrobial Resistance.MicrobiologyOpen · 2026Review
- Article
- Nanocarrier-based Drug Delivery Systems to Enhance Antimicrobial Photodynamic Therapy in Dental Applications: A Review.AAPS PharmSciTech · 2025Review
- Synthetic indole derivatives as an antibacterial agent inhibiting respiratory metabolism of multidrug-resistant gram-positive bacteria.Communications biology · 2024Article
- Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs.JAC-antimicrobial resistance · 2024Article
- Article
- In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020.Infection and drug resistance · 2024Article
- Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
- Cinacalcet exhibits rapid bactericidal and efficient anti-biofilm activities against multidrug-resistant Gram-positive pathogens.iScience · 2023Article
- Clinical efficacy and safety of linezolid in intensive care unit patients.Journal of intensive medicine · 2023Article
- Evidence of Antimicrobial Resistance in Bats and Its Planetary Health Impact for Surveillance of Zoonotic Spillover Events: A Scoping Review.International journal of environmental research and public health · 2022Article
- Self-Assembled Cationic Nanoparticles Combined with Curcumin against Multidrug-Resistant Bacteria.ACS omega · 2022Article
- Article
- Article
- The Role and Regulatory Network of the CiaRH Two-Component System in Streptococcal Species.Frontiers in microbiology · 2021Review
- A novel chresdihydrochalcone from Streptomyces chrestomyceticus exhibiting activity against Gram-positive bacteria.The Journal of antibiotics · 2020Article
- A case study onJAC-antimicrobial resistance · 2020Review
- Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens.Antimicrobial agents and chemotherapy · 2019Article
- A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Antimicrobial resistance in gram-positive bacteria remains a challenge in infectious diseases. The mission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to advance knowledge in the prevention, management, and treatment of these challenging infections to improve patient outcomes. Our committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope of the medical threat posed by these pathogens. Approved ARLG projects involving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing, and validating innovative assessments of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for "step-down" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neonatal intensive care units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes. This article outlines accomplishments, priorities, and challenges for research of infections caused by gram-positive organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.